0000000001237775

AUTHOR

Cristoforo Incorvaia

showing 8 related works from this author

SIRM-SIAAIC consensus, an Italian document on management of patients at risk of hypersensitivity reactions to contrast media

2020

Abstract Hypersensitivity reactions (HRs) to contrast media (CM) can be distinguished in immune-mediated (including allergic reactions) and non-immune-mediated reactions, even if clinical manifestations could be similar. Such manifestations range from mild skin eruptions to severe anaphylaxis, making it important for radiologists to know how to identify and manage them. A panel of experts from the Società Italiana di Radiologia Medica e Interventistica (SIRM) and the Società Italiana di Allergologia, Asma e Immunologia Clinica (SIAAIC) provided a consensus document on the management of patients who must undergo radiological investigations with CM. Consensus topics included: the risk stratif…

lcsh:Immunologic diseases. Allergyradiologic contrast media; hypersensitivity reactions; low-osmolar contrast agents; diagnosis; managementmedicine.medical_specialtyAllergyHypersensitivity reactionsReferralImmunologyReviewCulpritRadiologic contrast media03 medical and health sciences0302 clinical medicineDiagnosisHypersensitivity reactionmedicineImmunology and AllergyMedical historyIn patientLow-osmolar contrast agentsIntensive care medicineMolecular Biologybusiness.industryLow-osmolar contrast agentmedicine.diseaseManagement030228 respiratory systemRadiological weaponPremedicationbusinesslcsh:RC581-607AnaphylaxisDiagnosi030215 immunologyClinical and Molecular Allergy
researchProduct

Catching allergy by a simple questionnaire

2014

Background Identifying allergic rhinitis requires allergy testing, but the first-line referral for rhinitis are usually primary care physicians (PCP), who are not familiar with such tests. The availability of easy and simple tests to be used by PCP to suggest allergy should be very useful. Methods The Respiratory Allergy Prediction (RAP) test, based on 9 questions and previously validated by a panel of experts, was evaluated in this study. Results An overall number of 401 patients (48.6% males, age range 14–62 years) with respiratory symptoms was included. Of them, 89 (22.2%) showed negative results to SPT, while 312 (77.8%) had at least one positive result to SPT. Cohen’s kappa coefficient…

lcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAllergyReferralAllergymedicine.medical_treatmentImmunologyAllergy testingPrimary careAllergy testingSettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacistsAllergic rhinitisCohen's kappaAllergic rhinitimedicineImmunology and AllergyOriginal Researchbusiness.industrymedicine.diseaseAllergic rhinitis; Allergy; Allergy testing; Pharmacists; Primary care physicians; Immunology and AllergyTest (assessment)Primary care physicianNasal sprayPharmacistPrimary care physiciansAllergistslcsh:RC581-607business
researchProduct

Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

2021

International audience; The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to dete…

Allergen immunotherapyEndotypeMESH: AllergensMESH: HypersensitivityImmunologyDiseaseBioinformaticsMESH: Precision Medicine03 medical and health sciences0302 clinical medicinemolecular diagnosisHypersensitivityImmunology and AllergyMedicineHumansPrecision MedicineMESH: Desensitization Immunologic[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyMESH: Humansbusiness.industryMechanism (biology)MESH: GenomicsGenomicspersonalized medicineAllergenstreatable traitsMolecular diagnosticsOmics3. Good healthBiomarker (cell)omicsallergen immunotherapy; molecular diagnosis; omics; personalized medicine; treatable traits030228 respiratory systemDesensitization Immunologicallergen immunotherapyPersonalized medicinebusiness[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology030215 immunology
researchProduct

Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma.

2009

Background The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal choice. Objective To compare the different economic relevance, over a long evaluation time, of symptomatic pharmacologic therapy and sublingual immunotherapy (SLIT) in patients with allergic asthma. Methods Seventy patients with perennial allergic asthma, sensitized to dust mites, were enrolled; 50 of these patients were treated with SLIT against house dust mites and 20 were treated with symptomatic drugs. The patients were evaluated for …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAllergyAdolescentCost-Benefit AnalysisImmunologyPopulationAdministration SublingualFollow-Up StudieSublingual administrationDrug TherapyImmunopathologyInternal medicinemedicineImmunology and AllergyHumansCost-Benefit AnalysieducationChildAsthmaeducation.field_of_studyDrug Therapy; Combined Modality Therapy; Immunotherapy; Humans; Asthma; Child; Health Care Costs; Cost-Benefit Analysis; Adult; Middle Aged; Follow-Up Studies; Adolescent; Administration Sublingual; Male; Femalebusiness.industryRespiratory diseaseHealth Care CostsMiddle Agedmedicine.diseaseSlitCombined Modality TherapyAsthmaSurgeryHealth Care CostObservational studyFemaleImmunotherapybusinessHumanFollow-Up StudiesAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

Safety of sublingual immunotherapy started during the pollen season

2009

Sublingual immunotherapy (SLIT) is safer than subcutaneous immunotherapy (SCIT) and this has lead to the reconsideration of the use of ultra-rush schedules for SLIT. The aim of this study was to assess the safety of ultra-rush SLIT in pollen-allergic children according to different timing of administration in relation to the pollen season.In total, 34 children with pollen-induced rhinitis and 36 with pollen-induced asthma and rhinitis, were enrolled and assigned to three study groups: group 1 (n = 17 patients): conventional pre-seasonal-SLIT treatment; group 2 (n = 23 patients), seasonal SLIT ended before the pollen seasonal peak; group 3 (n = 30 patients), SLIT began after the pollen seaso…

Study groupsmedicine.medical_specialtyPediatricsAdolescentAdministration SublingualPollen Allergymedicine.disease_causePollenotorhinolaryngologic diseasesmedicineSubcutaneous immunotherapyHumansRhinitis Allergic Seasonal; Humans; Allergens; Asthma; Desensitization Immunologic; Child; Adolescent; Administration Sublingual; Pollen; Child PreschoolSublingual immunotherapyChildAsthmaPollen seasonbusiness.industryAllergenRhinitis Allergic Seasonalfood and beveragesGeneral MedicineAllergensmedicine.diseaseSlitAsthmaeye diseasesSurgerySLIT Ultra-RUSHDesensitization ImmunologicChild PreschoolPollensense organsbusinessHuman
researchProduct

Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years

2005

Background The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years. Objective To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than 5 years. Methods Sixty-five children (51 boys and 14 girls; age range, 38-80 months; mean ± SD age, 60 ± 10 years; median age, 60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were ho…

MalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyParietariaImmunologyAdministration SublingualSublingual administrationImmunopathologyAge Factors; Conjunctivitis Allergic; Humans; Allergens; Asthma; Rhinitis; Child; Desensitization Immunologic; Administration Sublingual; Male; Female; Child PreschoolHumansImmunology and AllergyMedicineAge FactorChildRhinitiRhinitisConjunctivitis Allergicbiologybusiness.industryCumulative doseAllergenAge FactorsAllergensbiology.organism_classificationAsthmaDiscontinuationClinical trialEl NiñoDesensitization ImmunologicChild PreschoolFemaleObservational studybusinessHumanAnnals of Allergy, Asthma & Immunology
researchProduct

Effectiveness of high dose sublingual immunotherapy to induce a stepdown of seasonal asthma: a pilot study

2009

There is ample evidence to support the efficacy of sublingual immunotherapy (SLIT) on allergic rhinitis, while there is less solid data regarding asthma. We evaluated the effects of a high dose birch SLIT on birch-induced rhinitis and asthma in a controlled study.This double-blind, placebo-controlled, randomised, single centre trial on SLIT with birch pollen allergen extract (Stallergenes, Antony, France) included 24 patients presenting severe rhinitis and slight to moderate asthma, 14 actively and 10 placebo treated. SLIT was performed by a pre-coseasonal protocol, and was repeated for 2 years. The study plan included a selection visit, a visit at the start of the first and the second trea…

AdultMalemedicine.medical_specialtyModerate asthmaDouble-Blind Method; Humans; Immunotherapy; Seasons; Adult; Asthma; Placebos; Pilot Projects; Middle Aged; Male; Female; Drug Administration RoutesPilot ProjectsPlacebolaw.inventionPlacebosSeasonal asthmaRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansSublingual immunotherapyPilot ProjectPlaceboAsthmabusiness.industryDrug Administration RoutesGeneral MedicineMiddle Agedmedicine.diseaseSlitAsthmaSurgerySingle centreFemaleSeasonsImmunotherapySeasonSLIT asthma allergybusinessHuman
researchProduct

Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

2021

International audience; Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe, or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage have been associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2). As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT1 R) axis associated with oxidative stress. This leads to insulin resistance …

ARIA groupAntioxidantMediterranean dietmedicine.medical_treatmentBrassicasulforaphaneMESH: Angiotensin-Converting Enzyme 2ReviewcabbageAntioxidants0302 clinical medicine10183 Swiss Institute of Allergy and Asthma ResearchVegetableskimchiFood sciencekimči0303 health sciencesMESH: NF-E2-Related Factor 23. Good healthAngiotensin-converting enzyme 22723 Immunology and Allergyfermentirana zelenjavaMESH: EcologyKeywords: Angiotensin converting enzyme 2NF-E2-Related Factor 2KEAP1-NRF2 SYSTEMImmunologyReviewsBrassicaNRF203 medical and health sciencesudc:578:635.34:663.15:COVID‐19angiotensin-converting enzyme 2CorrespondenceHumansMESH: SARS-CoV-2LactobacilluINTERMITTENT HYPOXIA2403 ImmunologyScience & TechnologyMESH: HumansAngiotensin II receptor type 1koronavirusMESH: Antioxidantsmedicine.disease030228 respiratory systemchemistryFermentationAllergymedicine.disease_causechemistry.chemical_compoundLINKING GUT MICROBIOTALactobacillalesLactobacillusImmunology and AllergyMESH: COVID-19Angiotensin converting enzyme 2030212 general & internal medicineOXIDATIVE STRESS[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyKeywords: Angiotensin converting enzyme 2; COVID-19; Lactobacillus; cabbage; diet; fermented vegetable; kimchi; sulforaphane.angiotensin-converting enzyme 2; cabbage; COVID-19; diet; fermented vegetable; kimchi; Lactobacillus; sulforaphane2. Zero hungerFOODSEcologyLactobacillalesMortality rate10177 Dermatology ClinicMEDITERRANEAN DIET1107 ImmunologyLife Sciences & Biomedicinefermented vegetable610 Medicine & healthSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologyMESH: FermentationMESH: Gastrointestinal MicrobiomeInsulin resistanceMESH: DietDownregulation and upregulationmedicine030304 developmental biologySARS-CoV-2COVID-19MESH: BrassicaCOVID-19; Lactobacillus; angiotensin-converting enzyme 2; cabbage; diet; fermented vegetable; kimchi; sulforaphane; Angiotensin-Converting Enzyme 2; Antioxidants; COVID-19; Diet; Ecology; Gastrointestinal Microbiome; Humans; Lactobacillales; NF-E2-Related Factor 2; Brassica; Fermentation; SARS-CoV-2; Vegetablesbiology.organism_classificationMESH: VegetablesDYSFUNCTIONDietGastrointestinal MicrobiomeLactobacillusMESH: Lactobacillalesangiotensin-converting enzyme 2 cabbage COVID-19 diet fermented vegetable kimchi Lactobacillus sulforaphanedietOxidative stressSulforaphane
researchProduct